|Title:||Classifying new anti-tuberculosis drugs: rationale and future perspectives||Authors:||Tiberi, Simon
Salazar-Lezama, Miguel Ángel
Migliori, Giovanni Battista
Caminero Luna, Jose A.
|UNESCO Clasification:||32 Ciencias médicas
320508 Enfermedades pulmonares
Linezolid, et al
|Issue Date:||2017||Journal:||International Journal of Infectious Diseases||Abstract:||The classification of anti-tuberculosis (TB) drugs is important as it helps the clinician to build an appropriate anti-TB regimen for multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB cases that do not fulfil the criteria for the shorter MDR-TB regimen. The World Health Organization (WHO) has recently approved a revision of the classification of new anti-TB drugs based on current evidence on each drug. In the previous WHO guidelines, the choice of drugs was based on efficacy and toxicity in a step-down manner, from group 1 first-line drugs and groups 2-5 second-line drugs, to group 5 drugs with potentially limited efficacy or limited clinical evidence. In the revised WHO classification, exclusively aimed at managing drug-resistant cases, medicines are again listed in hierarchical order from group A to group D. In parallel, a possible future classification is independently proposed. The aim of this viewpoint article is to describe the evolution in WHO TB classification (taking into account an independently proposed new classification) and recent changes in WHO guidance, while commenting on the differences between them. The latest evidence on the ex-group 5 drugs is also discussed.||URI:||http://hdl.handle.net/10553/47482||ISSN:||1201-9712||DOI:||10.1016/j.ijid.2016.10.026||Source:||International Journal of Infectious Diseases[ISSN 1201-9712],v. 56, p. 181-184|
|Appears in Collections:||Artículos|
checked on Aug 14, 2022
checked on May 21, 2022
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.